PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8944692-6 1996 Daunorubicin, vinblastine, etoposide, cyclosporin, and PSC-833, substrates/modulators of P-glycoprotein, were also potent inhibitors of E217G transport, and E217G competitively inhibited the ATP-dependent transport of daunorubicin. Etoposide 27-36 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 89-103 10218133-2 1999 P-glycoprotein (Pgp) located in the intestinal brush-border membrane may pump out orally absorbed etoposide and thus decrease etoposide"s absorption. Etoposide 98-107 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 10218133-2 1999 P-glycoprotein (Pgp) located in the intestinal brush-border membrane may pump out orally absorbed etoposide and thus decrease etoposide"s absorption. Etoposide 98-107 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-19 10218133-2 1999 P-glycoprotein (Pgp) located in the intestinal brush-border membrane may pump out orally absorbed etoposide and thus decrease etoposide"s absorption. Etoposide 126-135 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 10218133-2 1999 P-glycoprotein (Pgp) located in the intestinal brush-border membrane may pump out orally absorbed etoposide and thus decrease etoposide"s absorption. Etoposide 126-135 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-19 10218133-8 1999 These in vitro data supported the hypothesis that certain dietary components, possibly flavonoid-related compounds, may influence Pgp"s function in intestine and thus increase etoposide"s absorption. Etoposide 176-185 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 130-133 9864272-0 1998 Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution. Etoposide 40-49 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 11-25 9864272-1 1998 In this study, P-glycoprotein modulator effects on pharmacokinetics and central nervous system distribution of the chemotherapeutic agent etoposide were evaluated. Etoposide 138-147 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 15-29 7850926-1 1995 P-glycoprotein (Pgp) actively pumps a number of antineoplastic drugs, such as etoposide, out of cancer cells and causes multidrug resistance. Etoposide 78-87 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 7850926-1 1995 P-glycoprotein (Pgp) actively pumps a number of antineoplastic drugs, such as etoposide, out of cancer cells and causes multidrug resistance. Etoposide 78-87 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-19 7850926-3 1995 We hypothesized that inhibition of intestinal Pgp might decrease the efflux of etoposide from the blood into the intestinal lumen, thereby, increasing the bioavailability of etoposide. Etoposide 79-88 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 46-49 7850926-3 1995 We hypothesized that inhibition of intestinal Pgp might decrease the efflux of etoposide from the blood into the intestinal lumen, thereby, increasing the bioavailability of etoposide. Etoposide 174-183 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 46-49 7850926-12 1995 The present data confirm that intestinal Pgp mediates the efflux of etoposide and that the use of Pgp-inhibiting agents such as quinidine may increase the bioavailability of etoposide. Etoposide 68-77 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 41-44 7850926-12 1995 The present data confirm that intestinal Pgp mediates the efflux of etoposide and that the use of Pgp-inhibiting agents such as quinidine may increase the bioavailability of etoposide. Etoposide 174-183 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 41-44 7850926-12 1995 The present data confirm that intestinal Pgp mediates the efflux of etoposide and that the use of Pgp-inhibiting agents such as quinidine may increase the bioavailability of etoposide. Etoposide 174-183 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 98-101 24250670-1 2013 Etoposide, a widely used anticancer drug, exhibits low and variable oral bioavailability mainly because of being substrate for the efflux transporter, P-glycoprotein (P-gp). Etoposide 0-9 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 151-165 32376439-3 2020 The present study investigated if the BCS IV drug substance etoposide could be solubilized to a concentration saturating P-gp after oral administration. Etoposide 60-69 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 121-125 29635055-1 2018 The aim of the present work was to investigate the ability of nonionic surfactants to increase the oral absorption of the P-glycoprotein substrate etoposide in vitro and in vivo. Etoposide 147-156 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 122-136 29635055-4 2018 In cell cultures, polysorbate 20 (PS20) decreased P-glycoprotein mediated efflux of etoposide. Etoposide 84-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 50-64 29635055-9 2018 In conclusion, PS20 increases oral bioavailability of etoposide through inhibition of P-glycoprotein. Etoposide 54-63 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 86-100 28958946-7 2017 In contrast, the presence of TPGS significantly increased etoposide in-vivo rat permeability, attributable to P-gp inhibition, similarly to the effect of the potent P-gp inhibitor GF120918 (10microg/mL). Etoposide 58-67 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 110-114 24937381-0 2016 Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: an in vitro, ex vivo and in vivo investigations. Etoposide 81-90 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 94-108 24937381-1 2016 A receptor level interaction of etoposide with P-glycoprotein (P-gp) and subsequent intestinal efflux has an adverse effect on its oral absorption. Etoposide 32-41 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 47-61 24937381-1 2016 A receptor level interaction of etoposide with P-glycoprotein (P-gp) and subsequent intestinal efflux has an adverse effect on its oral absorption. Etoposide 32-41 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 63-67 24937381-2 2016 The present work is aimed to enhance the bioavailability of etoposide by co-administering it with quercetin (a P-gp inhibitor) in dual-loaded polymeric nanoparticle formulation. Etoposide 60-69 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 111-115 24969687-9 2015 These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR. Etoposide 35-38 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 78-92 24969687-9 2015 These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR. Etoposide 35-38 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 94-98 24969687-9 2015 These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR. Etoposide 181-184 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 78-92 24969687-9 2015 These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR. Etoposide 181-184 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 94-98 24351551-1 2014 Etoposide and morphine are well known P-glycoprotein (P-gp) substrates. Etoposide 0-9 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 38-52 24351551-1 2014 Etoposide and morphine are well known P-glycoprotein (P-gp) substrates. Etoposide 0-9 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 54-58 24351551-9 2014 That is, morphine and quinidine significantly increased the bioavailability of etoposide believed to be due to competitive P-gp inhibition in the intestine. Etoposide 79-88 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 123-127 24250670-1 2013 Etoposide, a widely used anticancer drug, exhibits low and variable oral bioavailability mainly because of being substrate for the efflux transporter, P-glycoprotein (P-gp). Etoposide 0-9 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 167-171 24250670-2 2013 Therefore, the present study was aimed to investigate the effect of D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) and PEG 400 as P-gp inhibitors on the intestinal absorption of etoposide. Etoposide 192-201 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 144-148 24250670-5 2013 The absorptive transport of etoposide was significantly enhanced (p < 0.001) in the presence of verapamil (100 mug/mL) and TPGS (over the concentration range of 0.002- 0.1 mg/mL), suggesting that the inhibition of P-gp located in the intestine may be involved in the enhancement of etoposide absorption. Etoposide 28-37 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 217-221 21506134-9 2011 Therefore, the enhanced oral bioavailability of etoposide in the presence of curcumin might be due mainly to inhibition of the P-gp efflux pump in the small intestine and possibly by reduced first-pass metabolism of etoposide in the small intestine by inhibition of CYP3A activity in rats. Etoposide 48-57 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 127-131 21623701-5 2011 In PCM rats, the CL(NR) (AUC(0- )) of intravenous etoposide was significantly slower (greater) than that in controls, because of the significant decrease in the hepatic CYP3A subfamily and P-gp. Etoposide 50-59 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 189-193 19183886-7 2009 The enhanced bioavailability of oral etoposide by kaempferol could have been due to an inhibition of cytochrom P450 (CYP) 3A and P-glycoprotein (P-gp) in the intestinal or decreased total body clearance in the liver by kaempferol. Etoposide 37-46 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 129-143 19414395-2 2009 This study was designed to investigate the effects of quercetin (3,5,7,3",4"-pentahydroxyflavanone), a P-gp and CYP3A inhibitor, on the pharmacokinetics of etoposide in rats. Etoposide 156-165 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 103-107 19414395-11 2009 The enhanced oral bioavailability of etoposide by quercetin could mainly be due to inhibition of P-gp-mediated efflux and CYP3A-catalyzed metabolism in the intestine by quercetin. Etoposide 37-46 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 97-101 19183886-7 2009 The enhanced bioavailability of oral etoposide by kaempferol could have been due to an inhibition of cytochrom P450 (CYP) 3A and P-glycoprotein (P-gp) in the intestinal or decreased total body clearance in the liver by kaempferol. Etoposide 37-46 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 145-149 19007041-1 2008 Etoposide is mainly metabolized by cytochrome P450 (CYP) 3A and is a substrate for P-glycoprotein (P-gp). Etoposide 0-9 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 83-97 18626752-2 2008 We investigated small-intestinal absorption of the P-glycoprotein (P-gp) substrates etoposide and digoxin in monkeys to clarify the influence of efflux transport on their intestinal permeability. Etoposide 84-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 51-65 18626752-10 2008 CONCLUSION: Low bioavailability of etoposide in monkeys is due to poor intestinal uptake resulting from low influx from the apical side, rather than secretion via P-gp. Etoposide 35-44 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 163-167 19007041-1 2008 Etoposide is mainly metabolized by cytochrome P450 (CYP) 3A and is a substrate for P-glycoprotein (P-gp). Etoposide 0-9 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 99-103 17315145-2 2007 It was reported that etoposide is a substrate for P-gp and metabolized mainly via CYP3A4 and to a lesser degree via CYP1A2 and 2E1. Etoposide 21-30 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 50-54 11290874-1 2001 Etoposide, an anti-neoplastic agent and a substrate of P-glycoprotein (P-gp), exhibits variable oral bioavailability. Etoposide 0-9 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 55-69 11290874-1 2001 Etoposide, an anti-neoplastic agent and a substrate of P-glycoprotein (P-gp), exhibits variable oral bioavailability. Etoposide 0-9 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 71-75